Semler Scientific (OTCMKTS:SMLR) PT Lowered to $60.00 at B. Riley

Semler Scientific (OTCMKTS:SMLRGet Rating) had its price target reduced by B. Riley from $70.00 to $60.00 in a research report issued on Tuesday, The Fly reports. B. Riley’s target price indicates a potential upside of 26.74% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Lake Street Capital reduced their price objective on Semler Scientific from $175.00 to $100.00 in a research note on Tuesday, March 1st. Zacks Investment Research raised shares of Semler Scientific from a “strong sell” rating to a “hold” rating in a report on Thursday, March 24th. TheStreet downgraded shares of Semler Scientific from a “b-” rating to a “c” rating in a report on Thursday, March 3rd. Finally, Colliers Securities reaffirmed a “buy” rating on shares of Semler Scientific in a report on Tuesday, March 22nd. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $117.75.

OTCMKTS:SMLR opened at $47.34 on Tuesday. The firm has a market capitalization of $320.02 million, a price-to-earnings ratio of 22.33 and a beta of 0.90. Semler Scientific has a one year low of $41.53 and a one year high of $153.21. The business has a fifty day moving average price of $50.02 and a 200-day moving average price of $79.62.

Semler Scientific (OTCMKTS:SMLRGet Rating) last posted its quarterly earnings data on Monday, May 2nd. The medical equipment provider reported $0.41 EPS for the quarter, missing the consensus estimate of $0.48 by ($0.07). Semler Scientific had a return on equity of 44.76% and a net margin of 32.48%. Research analysts anticipate that Semler Scientific will post 1.98 earnings per share for the current year.

In other Semler Scientific news, CEO Douglas Murphy-Chutorian sold 2,000 shares of the stock in a transaction dated Monday, February 28th. The shares were sold at an average price of $72.65, for a total transaction of $145,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.20% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Advisory Services Network LLC purchased a new stake in shares of Semler Scientific during the 3rd quarter valued at about $377,000. Russell Investments Group Ltd. purchased a new stake in shares of Semler Scientific during the 3rd quarter valued at about $36,000. Avalon Investment & Advisory purchased a new stake in shares of Semler Scientific during the 3rd quarter valued at about $4,155,000. Iridian Asset Management LLC CT purchased a new stake in shares of Semler Scientific during the 3rd quarter valued at about $4,951,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Semler Scientific during the 3rd quarter valued at about $18,849,000. 44.69% of the stock is owned by institutional investors and hedge funds.

Semler Scientific Company Profile (Get Rating)

Semler Scientific, Inc provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.

Recommended Stories

The Fly logo

Receive News & Ratings for Semler Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Semler Scientific and related companies with MarketBeat.com's FREE daily email newsletter.